title: Erythropoietin protects against apoptosis and increases expression of non-neuronal cell markers in the hypoxia-injured developing brain.
abstract: Erythropoietin (EPO) is a cytokine hormone with cytoprotective effects in many tissues including the brain. Although the benefits of administration of recombinant human EPO (rhEPO) for neonatal hypoxic brain injury have been demonstrated in neuronal tissue, the effect on non-neuronal cell populations is unclear. We tested the hypothesis that rhEPO would not only protect neuronal cells but also glial cells at a stage of brain development where their maturation was particularly sensitive, and also protect the vasculature. This was evaluated in a rat model of hypoxic injury. 1000 IU/kg rhEPO was delivered intraperitoneally at the start of 4 h hypoxia or normoxia. Treatment groups of neonatal rats (day of birth, at least N = 10 per group) were as follows: normoxia; normoxia plus rhEPO; hypoxia (8% FiO(2) delivered in temperature-controlled chambers); and hypoxia plus rhEPO. Day of birth in rats is equivalent to human gestation of 28-32 weeks. The effects of rhEPO administration, especially to non-neuronal cell populations, and the associated molecular pathways, were investigated. Apoptosis was increased with hypoxia and this was significantly reduced with rhEPO (p < 0.05). The neuronal marker, microtubule-associated protein-2, increased in expression (p < 0.05) when apoptosis was significantly reduced by rhEPO. In addition, compared with hypoxia alone, rhEPO-treated hypoxia had the following significant protein expression increases (p < 0.05): the intermediate filament structural protein nestin; myelin basic protein (oligodendrocytes); and glial fibrillary acidic protein (astrocytes). In conclusion, rhEPO protects the developing brain via anti-apoptotic mechanisms and promotes the health of non-neuronal as well as neuronal cell populations at a time when loss of these cells would have long-lasting effects on brain function.
authors.affiliation: Discipline of Medicine, School of Medicine, The University of Queensland at Princess Alexandra Hospital, Woolloongabba, Brisbane, Australia, 4102.
authors.forename: Miko
authors.initials: M
authors.lastname: Yamada
authors.forename: Christopher
authors.initials: C
authors.lastname: Burke
authors.forename: Paul
authors.initials: P
authors.lastname: Colditz
authors.forename: David W
authors.initials: DW
authors.lastname: Johnson
authors.forename: Glenda C
authors.initials: GC
authors.lastname: Gobe
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D017209:Apoptosis / Q000187:drug effects*; D001253:Astrocytes / Q000187:drug effects; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004921:Erythropoietin / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D020925:Hypoxia-Ischemia, Brain / Q000378:metabolism / Q000473:pathology* / Q000517:prevention & control; D007381:Intermediate Filament Proteins / Q000097:blood; D009419:Nerve Tissue Proteins / Q000097:blood / Q000378:metabolism; D064231:Nestin; D009474:Neurons / Q000187:drug effects; D009836:Oligodendroglia / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats; D017467:Receptors, Erythropoietin / Q000097:blood; D011994:Recombinant Proteins; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D007381:Intermediate Filament Proteins; C577484:NES protein, human; D009419:Nerve Tissue Proteins; C577486:Nes protein, rat; D064231:Nestin; D017467:Receptors, Erythropoietin; D011994:Recombinant Proteins; D004921:Erythropoietin